- Home
- AIRS vs APLT Comparison
AIRS vs APLT Comparison
Compare AIRS & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- APLT
- Stock Information
- Founded
- AIRS 2012
- APLT 2016
- Country
- AIRS United States
- APLT United States
- Employees
- AIRS N/A
- APLT N/A
- Industry
- AIRS Medical/Nursing Services
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- APLT Health Care
- Exchange
- AIRS Nasdaq
- APLT Nasdaq
- Market Cap
- AIRS 166.3M
- APLT 178.6M
- IPO Year
- AIRS 2021
- APLT 2019
- Fundamental
- Price
- AIRS $10.63
- APLT $1.25
- Analyst Decision
- AIRS Hold
- APLT Buy
- Analyst Count
- AIRS 3
- APLT 5
- Target Price
- AIRS $3.75
- APLT $4.13
- AVG Volume (30 Days)
- AIRS 974.7K
- APLT 12.4M
- Earning Date
- AIRS 11-07-2025
- APLT 11-06-2025
- Dividend Yield
- AIRS N/A
- APLT N/A
- EPS Growth
- AIRS N/A
- APLT N/A
- EPS
- AIRS N/A
- APLT N/A
- Revenue
- AIRS $165,109,000.00
- APLT $121,000.00
- Revenue This Year
- AIRS N/A
- APLT N/A
- Revenue Next Year
- AIRS $5.14
- APLT $5,935.35
- P/E Ratio
- AIRS N/A
- APLT N/A
- Revenue Growth
- AIRS N/A
- APLT N/A
- 52 Week Low
- AIRS $1.53
- APLT $0.30
- 52 Week High
- AIRS $10.68
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- AIRS 85.29
- APLT 68.25
- Support Level
- AIRS $7.44
- APLT $0.90
- Resistance Level
- AIRS $9.11
- APLT $1.16
- Average True Range (ATR)
- AIRS 0.65
- APLT 0.21
- MACD
- AIRS 0.24
- APLT 0.03
- Stochastic Oscillator
- AIRS 98.86
- APLT 88.15
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.